The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

Slides:

Advertisements

Similar presentations

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by CapeOX plus BEV or single agent (s/a) BEV.

Advertisements

The Nurse View: Management of Pancreatic Cancer

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A Multidisciplinary Team Approach Challenges and Best Practices in Cushing Disease.

New Psoriasis Treatments

New ESMO Guidance on Tumor Sidedness in mCRC

The Nurse View Key Insights Along the CML Continuum

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Perspectives on Triple-Negative Breast Cancer

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Optimizing Use of Biological Agents in Ulcerative Colitis

The Nurse View.

Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome

Patient 1: 53-Year-Old Man With CVD Risk Factors

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Individualizing Prophylaxis in Hemophilia

Neoadjuvant Therapy in HER2-Positive Breast Cancer

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Before and After: Patient Cases in Onychomycosis

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Clinical Considerations in Evidence-based Management of GIST

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

Optimizing Management of Advanced Bladder Cancer

Best Practices in Metastatic Colorectal Cancer

Are We Closer to Personalized Medicine in MS?

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Team-Based Perspectives on Successful Approaches in Treating Obesity

Seizures in the Elderly: Treatment and Special Considerations

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

From Symptom Management to Communication in Advanced GI Cancers

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

ADVANCED PARKINSON'S DISEASE:

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing the Treatment of IBD With Biologics

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

Program Goals Overview Is NEDA a Reasonable Target?

The Road to Quality Improvement in HER2-Positive Breast Cancer

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

Cancer-Associated Thrombosis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Management of Advanced Pancreatic Adenocarcinoma

Oral Prostacyclin Pathway Agents in PAH

Incorporating Prostacyclins Into Practice

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Patient Stories in PAH: Sequential Therapy in a FC II Patient

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Program Goals Overview Is NEDA a Reasonable Target?

Prostacyclin Pathway Agents in Action

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Issues in Patients With Severe Epilepsy

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Clinical Considerations in Evidence-based Management of GIST

The Nurse View.

Ask the Psoriasis Expert

Understanding the Expanding Armamentarium for GIST

Uncovering the Right Sequence

Presentation transcript:

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer

Targeted Therapies Used in the Treatment of Patients With mCRC

Case 1: 70-year-old Man With Inoperable mCRC (cont)

Ziv-aflibercept: Potential Side Effects

Ziv-aflibercept: Monitoring for Side Effects

Case 2: 47-year-old Woman With Disease Recurrence Following an Initial Diagnosis of Stage IIIC Colon Cancer

Regorafenib: Key Patient Education Issues

Regorafinib: Potential Side Effects

Case 2: 47-year-old Woman With mCRC Receiving Regorafenib

Regorafinib: Monitoring for Side Effects

Hand-Foot Skin Reaction

Strategies for Combating Fatigue

The Importance of Patient Education

Strategies for Prevention and Treatment of HFSR

Hand-Foot Skin Reaction (cont)

Hand-Foot Syndrome vs Hand-Foot Skin Reaction

Summary: Strategies for Optimizing Use of New Targeted Agents in mCRC

Abbreviations

References

References (cont)

References (cont)